Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...

BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX), its partner for the Comirnaty COVID-19 vaccine, made legal submissions to London's Court of Appeal on Thursday seeking to overturn a prior court ruling ...

Johnson & Johnson JNJ and Pfizer PFE rank among the world’s largest pharmaceutical companies, each with broad and diversified healthcare portfolios. J&J operates primarily through its pharmaceuticals ...

In May 2024, Pfizer settled 10,000 lawsuits alleging it concealed the cancer risks associated with its Zantac heartburn medication, marking the largest resolution in the litigation.

Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents, in the latest round of a long ...

Pfizer Inc. s fourth-quarter profit fell by half as worsening generic competition and unfavorable currency rates reduced sales, and higher research spending and legal costs also hurt the bottom line.

Pfizer, BioNTech challenge Moderna’s COVID vaccine patent win in U.K. Jul. 10, 2025 8:08 AM ET Pfizer Inc. (PFE) Stock, MRNA Stock, BNTX Stock By: Dulan Lokuwithana, SA News Editor 1 Comment ...